Browse Studies — Arctuva

Phase 1

A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

Estimated

~$10 – $8,750

Iambic Therapeutics, IncNCT06253871

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal res…

Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more

Estimated

~$10 – $1,125

Tempus AINCT07211178

Prospective Evaluation of Outcomes for HER2-positive Breast Cancer (PRO-HER2)

The goal of this observational study is to better understand links between patient or tumor characteristics and outcomes in HER2-positive breast cancer.

HER2 + Breast Cancer

Estimated

~$10 – $1,125

Priyanka SharmaNCT06603597

Phase 1

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tum…

Locally Advanced CancerMetastatic CancerHER2+2 more

Estimated

~$10 – $6,250

Vanderbilt-Ingram Cancer CenterNCT06828588